etravirine (TMC-125)

New non-nuke approved

Jill Sergeant — Thu, 04 Jun 2009 23:27:51 -0700

A new Non-Nucleoside Reverse Transcriptase InhibitorA type of anti-HIV drug which works by interfering with an enzyme, reverse transcriptase, that HIV needs to reproduce. – etravirine – will be listed on the Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) from July 1.

AIDS 2008: Is the HIV drug pipeline drying up?

David Menadue — Tue, 23 Sep 2008 19:21:56 -0700

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia.

Etravirine promising for those with NNRTI resistance

admin — Mon, 21 Jul 2008 18:13:44 -0700

An encouraging outcome of the DUET studies is that etravirine is effective against HIV mutations resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to existing NNRTIs, efavirenz and nevirapine.

CROI 2007: A great leap forward

Paul Kidd — Wed, 21 Mar 2007 07:10:12 -0700

A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years.

ASHM 2006: Strategies for coping with multiple drug resistance

Paul Kidd — Wed, 20 Dec 2006 06:07:10 -0800

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. mutations continues to be a significant challenge for HIV clinicians, and their patients.

New tricks

Wed, 20 Dec 2006 06:06:45 -0800

Two new drugs have recently become available through the Special Access SchemeBefore a drug has been approved, manufacturers often provide the drug free of charge to people who cannot participate in a clinical trial and who meet certain criteria under a Special Access Scheme (SAS). , providing people with limited treatment options two important new possibilities. KIRSTY MACHON reports.

SAS programs open for TMC-125, MK-0518

Wed, 01 Nov 2006 16:18:39 -0800

Special Access Scheme (SASBefore a drug has been approved, manufacturers often provide the drug free of charge to people who cannot participate in a clinical trial and who meet certain criteria under a Special Access Scheme (SAS). ) programs are now open to allow early access to two new antiretroviralA medication or other substance which is active against retroviruses such as HIV. drugs. This scheme allows for access to these medications while they are still in the final stages of clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. research.

Time to deliver

John Daye — Wed, 04 Oct 2006 07:10:48 -0700

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports.

Rocky Mountain CROI

Paul Kidd — Wed, 26 Apr 2006 07:08:00 -0700

The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story.